IMA1 Antibody

What is IMA1 and what is its role in plant immunity?

IMA1 is a key regulatory protein involved in modulating plant immunity and iron acquisition pathways. It plays a critical role in the crosstalk between nutrient uptake and immune responses in plants. Research demonstrates that IMA1 affects both root colonization by microbes and resistance to bacterial foliar pathogens, representing an adaptive molecular mechanism of nutritional immunity .

Methodologically, IMA1 function can be studied through:

• Gene expression analysis under various iron conditions

• Protein localization using fluorescent tags (EYFP-IMA1, mCitrine-IMA1)

• Phenotypic assessment of mutant lines (e.g., ima8x)

• Measurement of iron deficiency responses such as Ferric Chelate Reductase (FCR) activity

IMA1 is particularly interesting because it represents a convergence point between nutritional status and immune response signaling.

How does iMab differ from IMA1, and what are its research applications?

While similar in nomenclature, iMab and IMA1 are entirely different molecules with distinct research applications:

iMab functions as an anti-CD4 antibody that prevents HIV-1 infection in a non-competitive manner and has become an important component in advanced antibody engineering approaches . More recently, "iMab" has also been used to refer to an antibody that selectively binds to i-Motifs (quadruplex nucleic acid conformations) , representing a distinct research tool.

What are i-shaped antibodies (iAbs) and how do they relate to conventional antibody structures?

i-shaped antibodies (iAbs) represent a specialized antibody conformation distinct from the standard Y-shaped configuration of conventional antibodies. They are characterized by unique arrangements of the Fab arms that create an "i" shape rather than a "Y" shape.

Research has identified different mechanisms that facilitate iAb formation:

• Heavy chain variable (VH) domain exchange between Fabs (e.g., in 2G12 antibody from HIV patients)

• Affinity-driven intramolecular Fab-Fab homotypic interactions between VH domain β-strands A, B, D, and E (e.g., in DH851 and DH898 antibodies)

These conformational arrangements have significant implications for antigen binding properties. Electron microscopy studies have shown that engineered iAbs can exist in mixed populations, with some antibodies adopting the i-shaped conformation while others maintain a standard Y-shape. For example, one engineered variant showed approximately 64% of particles adopting the iAb conformation .

How does IMA1 spatially regulate iron acquisition in response to microbial signals?

IMA1 exhibits sophisticated spatial regulation in response to microbial elicitors like flg22 (a bacterial flagellin peptide). This regulation plays a critical role in how plants balance iron acquisition with immune responses.

The mechanistic details include:

• Under iron deficiency (-Fe), IMA1 is strongly induced in all root cell layers

• When plants detect microbial signals (flg22), IMA1 protein is selectively depleted in the ground tissue

• This depletion occurs post-transcriptionally, as flg22 actually increases IMA1 transcriptional activity in the ground tissue under iron deficiency

• The spatial regulation of IMA1 affects iron uptake through modulation of IRT1 (Iron-Regulated Transporter 1) expression and FCR activity

Importantly, this regulatory mechanism appears to be cell-type specific. When IMA1 is constitutively expressed in the epidermis and cortex (using tissue-specific promoters like pPGP4), plants become insensitive to flg22-mediated repression of iron uptake. This indicates that the spatial distribution of IMA1 is crucial for appropriate immune-nutritional responses .

What methodological approaches are most effective for designing trispecific antibodies incorporating iMab?

Designing trispecific antibodies that include iMab requires sophisticated antibody engineering approaches. Based on recent research, the DVD-Ig (dual-variable-domain immunoglobulin) format has proven effective for this purpose.

The methodological process involves:

• Cloning sequences for two scFvs in frame with connecting G4S linkers (GGGGSGGGGS) on both N and C termini of a full IgG1 antibody

• Fusing variable domains of heavy chains with appropriate linkers, followed by constant regions

• For light chains, connecting variable domains via identical linkers, followed by constant regions

• Cotransfecting plasmids encoding heavy and light chains into expression cells (e.g., HEK293F) at optimized ratios

• Purification and characterization through binding assays to confirm retention of specificity

This approach has yielded successful trispecific antibodies combining iMab with PRO140 (anti-CCR5) and various broadly neutralizing antibodies against HIV-1, such as 10E8, PGDM1400, and PGT121 . These trispecific molecules successfully maintained binding activity to CD4 receptor, CCR5 co-receptor, and HIV-1 antigens from different subtypes.

How can researchers optimize the selectivity of iMab antibody for i-Motif structures?

The iMab antibody used for detecting i-Motifs (quadruplex nucleic acid conformations) requires careful optimization to ensure selectivity. Recent research has highlighted several critical factors:

• Buffer composition during binding and washing steps strongly influences antibody selectivity

• DNA concentration affects the formation of intermolecular versus intramolecular i-Motifs

• Blocking conditions must be carefully optimized to prevent non-specific binding

• Washing procedures significantly impact the signal-to-noise ratio

NMR studies have confirmed that iMab recognizes both intramolecular and intermolecular i-Motifs, which has important implications for experimental design. Some C-rich sequences previously thought not to form i-Motifs can actually form intermolecular i-Motifs that are recognized by iMab . Therefore, researchers should conduct careful controls when using this antibody for i-Motif detection.

What are the key physicochemical challenges in developing bispecific antibodies incorporating iMab?

Developing bispecific antibodies that incorporate iMab presents significant physicochemical challenges that require careful engineering and characterization:

Initial bispecific antibodies combining 10E8 (anti-MPER) with iMab demonstrated physicochemical heterogeneity, evidenced by double peaks in size exclusion chromatography (SEC) profiles . This heterogeneity cannot be attributed to antibody aggregation but rather reflects conformational variability.

To address these challenges, researchers have employed several strategies:

• Introducing point mutations in chimeric constructs

• Grafting CDR regions from other antibodies into chimeric mutants

• Testing multiple variants for optimal physicochemical properties

These efforts led to the development of improved variants like 10E8 V2.0/iMab, which demonstrated physicochemical homogeneity while retaining potent antiviral activity . Importantly, the optimal 10E8 chimeric variant differed depending on whether it was paired with P140 or iMab, highlighting the context-dependent nature of bispecific antibody properties.

How does IMA1 modulate pattern-triggered immunity (PTI) components in plants?

IMA1 plays a complex role in modulating pattern-triggered immunity (PTI) components in plants. Experimental data shows that:

• Overexpression of IMA1 affects the expression levels of key flg22-dependent PTI components

• The repression of iron deficiency responses by flg22 is abolished when IMA1 is continuously expressed

• flg22 modulation of iron deficiency responses involves downregulation of IMA genes

• IMA1 signaling can perturb expression of PTI response genes

This interrelationship suggests that IMA1 serves as a regulatory node connecting nutrient acquisition pathways with immune responses. For researchers studying plant immunity, this finding indicates that iron nutritional status and IMA1 expression should be considered when interpreting PTI responses.

What controls should be included when using iMab antibody for i-Motif detection?

When using iMab antibody for i-Motif detection, researchers should include several critical controls:

• pH controls: Since i-Motif formation is pH-dependent, samples prepared at neutral pH (where i-Motifs typically do not form) versus acidic pH (where they do form)

• Sequence controls: C-rich sequences known to form i-Motifs versus mutated sequences that cannot form these structures

• DNA concentration gradients: To distinguish between intermolecular and intramolecular i-Motif formation

• Buffer composition controls: Different binding and washing buffers to establish optimal selectivity conditions

• Competition assays: Using unlabeled i-Motif-forming sequences to demonstrate specificity

Additionally, NMR spectroscopy can provide definitive confirmation of i-Motif formation in test sequences, serving as an orthogonal validation method for antibody-based detection.

How can researchers accurately assess the neutralization potency of bispecific antibodies containing iMab?

To accurately assess the neutralization potency of bispecific antibodies containing iMab, researchers should employ a comprehensive approach that includes:

• Testing against diverse virus panels representing global HIV-1 diversity:

  • One study tested bispecific antibodies against a panel of 118 HIV-1 pseudotyped viruses from diverse clades

  • Additional testing against a second panel of 200 HIV-1 isolates belonging to clade C (the dominant subtype accounting for ~50% of new infections)

• Calculating IC50 values (concentration that provides 50% inhibition):

  • The most potent bispecific antibody, 10E8 V2.0/iMab, neutralized viruses with a mean IC50 of 0.002 μg/mL

• In vivo validation in appropriate animal models:

  • Humanized mouse models can be used to assess both therapeutic potential (virus load reduction in infected animals) and prophylactic protection (prevention of infection when administered prior to virus challenge)

• Physicochemical characterization:

  • Size exclusion chromatography to assess purity and homogeneity

  • Binding assays to confirm retention of specificity for each target

This multi-faceted approach ensures that neutralization data is robust and predictive of clinical utility.

What factors influence IMA1 mobility and function in different cell types?

IMA1 mobility and function across different cell types is influenced by several key factors:

• Cell-type specific expression: IMA1 has been shown to be a mobile signal, but its ability to induce responses like IRT1 expression depends on local expression in specific tissues

• Transcriptional regulation: Iron deficiency strongly induces IMA1 transcription in all cell layers, which can be further modified by immune signals

• Post-transcriptional regulation: Despite increased transcriptional activity in some contexts, protein levels can be reduced through post-transcriptional mechanisms

• Spatial constraints: Studies using tissue-specific promoters showed that IMA1 expression in epidermis and cortex is necessary to induce IRT1, indicating that mobility from other tissues is insufficient

These findings suggest that while IMA1 has some mobile properties, its functional impact is constrained by tissue-specific factors that researchers should consider when designing experiments to study its role in different cellular contexts.

How does the i-shaped antibody conformation affect antigen binding properties?

The i-shaped antibody conformation significantly alters antigen binding properties compared to conventional Y-shaped antibodies:

• Conformational distribution: Electron microscopy studies show that engineered iAbs exist in mixed populations, with some antibodies adopting the i-shaped conformation (29-64% depending on the variant) while others maintain the standard Y-shape

• Dimerization potential: Some iAb variants (e.g., iAb aff2) can form dimers where Fabs associate in an intermolecular head-to-head manner

• Antigen binding: The altered orientation of binding domains in iAbs can affect epitope accessibility and binding kinetics

• Context-dependent properties: The optimal conformation can differ depending on what other antibody components are paired together, as seen with different 10E8 variants when combined with P140 versus iMab

Understanding these conformational properties is crucial for researchers designing antibodies for specific applications, as they can significantly impact function and physicochemical properties.

What are the future prospects for combining IMA1 research with antibody-based detection methods?

The integration of IMA1 research with antibody-based detection methods presents several promising research directions:

• Development of specific antibodies against IMA1 and related proteins to:

  • Track protein localization and movement between tissues

  • Quantify protein levels in different conditions

  • Immunoprecipitate IMA1 to identify interaction partners

• Application of advanced antibody engineering approaches to study IMA1:

  • Bispecific antibodies targeting IMA1 and potential interaction partners

  • Intrabodies for in vivo visualization of IMA1 dynamics

  • Nanobodies for super-resolution microscopy of IMA1 distribution

• Translation of insights from plant IMA1 to biomedical applications:

  • Exploring potential homologs or functional analogs in other organisms

  • Investigating connections between iron homeostasis and immunity across kingdoms

These approaches could provide valuable insights into the molecular mechanisms underlying IMA1 function and potentially reveal new therapeutic targets at the intersection of nutrition and immunity.

How might the principles of iMab development inform other antibody engineering applications?

The development of iMab and its application in HIV-1 neutralization provides several valuable principles that could inform other antibody engineering efforts:

• Context-dependent optimization:

  • The finding that optimal 10E8 variants differ depending on pairing partner suggests that antibody optimization should be conducted in the final multispecific format rather than optimizing components separately

• Structure-guided modifications:

  • The successful engineering of bispecific antibodies with improved physicochemical properties demonstrates the value of rational design approaches

• Conformational tuning:

  • The ability to manipulate antibody conformation through specific mutations, as seen with i-shaped antibodies , could be exploited for applications requiring specific spatial arrangements of binding domains

• Targeting entry mechanisms:

  • The impressive potency of iMab-containing bispecific antibodies against HIV-1 suggests that targeting cellular entry factors might be an effective strategy for other viral diseases

These principles could be applied to develop novel antibody therapies for infectious diseases, cancer, and autoimmune conditions, potentially leading to more potent and specific treatments with improved pharmacological properties.